ATOS Stock Analysis: Buy, Sell, or Hold?
ATOS - Atossa Therapeutics, Inc. Common Stock
$2.17
0.10 (4.83%)
▲
5d:
-8.05%
30d:
+2.36%
90d:
-59.29%
HOLD
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 11, 2026
6d
Get Alerted When ATOS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ATOS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ATOS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ATOS is currently trading at $2.17, which is considered slightly low relative to its 30-day fair value range of $2.11 to $2.46.
Technical Outlook: Technically, ATOS is in a strong downtrend. Immediate support is located at $2.05, while resistance sits at $2.60. The stock is showing strong short-term momentum, up 4.8% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $22.00 (+913.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ATOS is in a strong downtrend. Immediate support is located at $2.05, while resistance sits at $2.60. The stock is showing strong short-term momentum, up 4.8% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $22.00 (+913.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.11 -
$2.46
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
90.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.8%)
- BULLISH: Trading 913.8% below Wall St target ($22.00)
- CAUTION: Recommendation downgraded due to -8.1% 5-day decline
Trading Range Analysis
30-Day Trading Range
$2.11 -
$2.46
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$0.29
(13.6%)
Support & Resistance Levels
Support Level
$2.05
Resistance Level
$2.60
Current Trend
Strong Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.50
Wall Street Target
$22.00
(+913.8%)
Share & Embed Analysis
Last updated: August 04, 2026 12:20 AM ET
Data refreshes hourly during market hours. Next update: 1:20 AM
Data refreshes hourly during market hours. Next update: 1:20 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATOS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 50 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$52 | 54 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$834 | 58 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$267 | 60 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 56 HOLD |
